{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-25-000004","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.330170+00:00","generated_at":"2026-05-28T05:09:19.741871+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas updates Phase 3 vepdegestrant combo trials; VERITAC-2 topline data expected Q1 2025","bullets":["Topline data for VERITAC-2 Phase 3 monotherapy trial of vepdegestrant expected in Q1 2025.","First-line Phase 3 combo with Pfizer's atirmociclib planned for 2025; VERITAC-3 (palbociclib combo) discontinued.","Phase 1 trial of ARV-102 (LRRK2 degrader) in Parkinson's disease initiated; data at AD/PD conference April 2025.","Alex Santini appointed interim CCO effective Jan 17, 2025; John Northcott leaving for personal reasons.","IND filing for KRAS G12D degrader and initial data from ARV-393 (BCL6 degrader) expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-25-000004","json":"https://secwatch.observer/filing/0001655759-25-000004.json","markdown":"https://secwatch.observer/filing/0001655759-25-000004.md","text":"https://secwatch.observer/filing/0001655759-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/0001655759-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/arvn-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:09:19.741871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}